The Immuno-Oncology Market to look through AI-based genomics at a CAGR of 14%

The field of immuno-oncology involves the use of the body's immune system to fight cancer. In recent years, this approach has gained significant traction in the cancer treatment landscape, with the emergence of several novel immuno-oncology therapies. These therapies have shown remarkable efficacy in clinical trials, leading to their approval by regulatory bodies and their subsequent adoption by healthcare providers. The immuno-oncology market has witnessed significant growth in recent years, and this trend is expected to continue in the coming years.

Market Size and Growth:

The global immuno-oncology market was valued at USD 10,600 million in 2019 and is expected to grow at a CAGR of 14 % from 2019 to 2029. The market growth is primarily driven by factors such as the increasing prevalence of cancer, the growing adoption of immuno-oncology therapies, and the development of new and innovative immuno-oncology drugs.

You can request sample here @ https://www.persistencemarketresearch.com/samples/11329

Companies:

Amgen, Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck & Co, Inc.
Novartis AG
Pfizer Inc.
Sanofi.

Drivers and Restraints:

The immuno-oncology market has witnessed significant growth in recent years, driven by a range of factors. One key driver is the increasing prevalence of cancer worldwide, which has created a growing need for more effective treatments. Additionally, advances in technology and research have led to the development of new and innovative immuno-oncology therapies, including checkpoint inhibitors and CAR-T cell therapy. However, there are also several significant restraints to the market, including the high cost of these treatments, limited access to care in some regions, and the potential for severe side effects. Additionally, the complexity of the immune system and the variability of patient responses to treatment pose significant challenges for the development and commercialization of new therapies. Despite these challenges, the immuno-oncology market is expected to continue growing in the coming years as researchers and companies work to overcome these obstacles and bring new and innovative therapies to patients in need.

Get Methodology Report here @ https://www.persistencemarketresearch.com/methodology/11329

Therapy Type:

Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others (Immune Cell Therapy, etc.)

Therapeutic Area:

Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers

End User:

Hospitals
Clinics
Ambulatory Surgical Centers

If You Want To Know The Business Opportunity/Market Value, Purchase The Premium Insight @ https://www.persistencemarketresearch.com/checkout/11329

Related Reports:

Neurology Contract Research Organization Market
https://www.persistencemarketresearch.com/market-research/neurology-contract-research-organization-market.asp

Libya Dialysis Machines Market
https://www.persistencemarketresearch.com/market-research/libya-dialysis-machines-market.asp

Lensometer Market
https://www.persistencemarketresearch.com/market-research/lensometer-market.asp

Asian Breast Implants Market
https://www.persistencemarketresearch.com/market-research/asian-breast-implants-market.asp

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.